Inflexxion Webinar on the Challenge of Measuring Post-Market Abuse Potential of Prescription Opioids

Share Article

Webinar will address some of Inflexxion’s recent findings that highlight the relationship between prescription opioid abuse and prescription opioid availability.

News Image

Inflexxion, a company that develops behavioral change programs that reduce health-related risks, improve clinical outcomes, positively influence quality of care, and improve public health, announces its free live webinar, “The Challenge of Measuring Post-Market Abuse Potential of Prescription Opioids. Can we do better?” on April 23 from 1:00-2:00pm EDT. Click here to register now.

The webinar will focus on new data collected by Inflexxion’s proprietary NAVIPPRO® surveillance system. NAVIPPRO offers real-time monitoring of patterns and trends of prescription medication use nationwide. With its real-time monitoring system that includes data from hundreds of substance abuse treatment centers across the country, NAVIPPRO detects changes in prescription opioid and stimulant use patterns, including the impact of new products and abuse deterrent formulations, and estimates the relative rates of abuse and misuse.

“Preliminary findings suggest that the association between abuse of prescription opioids and prescribed availability is not proportional. In fact, while the association varies somewhat by product, in general, the association appears stronger in geographic areas with low levels of volume but substantially weaker to non-existent in areas with higher levels of volume. This suggests a curvilinear, rather than linear, relationship between abuse and product availability, with a possible ‘ceiling’ effect as the volume of prescribed availability becomes large,” says Ryan Black, PhD, Director of Biostatistics and Methodology at Inflexxion. “When prescription volume is appropriately modeled, the relative estimates of abuse across well-known prescription opioids changes substantially as compared to when volume is assumed to have a proportional relationship.”

NAVIPPRO (National Addictions Vigilance Intervention and Prevention Program) is a proprietary turnkey solution developed by Inflexxion with support from the National Institutes of Health (NIH) and the National Institutes of Drug Abuse (NIDA). NAVIPPRO utilizes proprietary data sources to offer real-time monitoring of patterns and trends of prescription medication use, including the impact of new products and abuse deterrent formulations. For more information please visit

About Inflexxion
Founded in 1989, Inflexxion develops scientifically based, interactive technologies and collects data in innovative ways through clinical settings, Internet WebCrawler technology, and web-surveys regarding health status, health behaviors, health beliefs, and health outcomes. Partners and customers rely on Inflexxion for online programs that reduce health-related risks, enhance clinical outcomes, and positively influence quality of care. Inflexxion analyzes and disseminates health-related data for purposes of surveillance, risk management, epidemiological studies, quality improvement, and outcome measurement used by healthcare organizations and regulatory authorities to help improve care and inform public policy. Through education, Inflexxion changes behaviors by providing online, empirically driven, health-related approaches to healthcare providers, patients, and the general population in the areas of addiction and recovery, pain management, and prescription drug safety. For more information please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Elsbeth McSorley
Visit website